Punch: Preliminary results from a phase II study of intra‑arterial chemotherapy (IAC) combined with tislelizumab and bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer (HR NMIBC).

Authors

Zongren Wang

Department of Urology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

Zongren Wang , Wenhao Zhan , Bin Huang , Cheng Luo , Lingwu Chen , Junxing Chen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Genitourinary Cancers Symposium

bookmark_border

Preliminary results from a phase II study of tislelizumab combined with radiotherapy as bladder-preserving treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).

First Author: Zhiyong Li

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (NMIBC).

First Author: Ashish M. Kamat

insert_chart_outlined

Poster

2024 ASCO Genitourinary Cancers Symposium

bookmark_border

RC48-ADC versus BCG in adjuvant treatment of high-risk non-muscle-invasive bladder cancer with HER2 over-expression: A real-world retrospective study.

First Author: Haoyang Liu

insert_chart_outlined

Poster

2024 ASCO Genitourinary Cancers Symposium

bookmark_border

Pembrolizumab with favezelimab or vibostolimab for patients with bacillus Calmette-Guérin (BCG)–unresponsive high-risk (HR) non–muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 cohort C.

First Author: Girish S. Kulkarni